Synexa is a specialist biomarker services provider, with deep expertise in the design and delivery of biomarker strategies for global biopharma clients.
Location: Netherlands, South Holland, Leiden
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Gilde Heal... | gildehealt... |
Mentions in press and media 4
| Date | Title | Description |
| 11.06.2025 | EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio | EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio Wed, Jun 11, 2025 09:30 CET Report this content Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as... |
| 08.06.2023 | Accelerating TB Vaccine Development: Insights from Microsampling, Biomarkers and Data Analysis, Upcoming Webinar Hosted by Xtalks | This webinar aims to explore critical aspects of TB vaccine development. TORONTO (PRWEB) June 08, 2023 Tuberculosis (TB) continues to be a global health threat, particularly affecting vulnerable populations, including children. This webinar... |
| 02.11.2022 | Clinically-Relevant Biomarker Strategies in Drug Development and the Potential of Machine-Learning for Biomarker Assessment, Upcoming Webinar Hosted by Xtalks | The real value of biomarker insights have not been fully realized due the limitations in the development and implementation of effective biomarker strategies in many clinical programmes across therapeutic areas, resulting in the absence of ... |
| 20.06.2022 | Alternative Approaches to Functional and Phenotypic Assays Using Multiparameter Flow Cytometry, Upcoming Webinar Hosted by Xtalks | These alternative applications require additional analytical considerations and optimizations at an assay-specific level. TORONTO (PRWEB) June 20, 2022 The applications of multiparameter flow cytometry are rapidly expanding due to the versa... |